$177 Million is the total value of Kinnevik AB (publ)'s 3 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TDOC | Teladoc Health, Inc. | $87,118,748 | -6.7% | 3,683,668 | 0.0% | 49.14% | -37.2% | |
| RXRX | New | Recursion Pharmaceuticals, Inc. | $59,005,100 | – | 7,653,061 | +100.0% | 33.28% | – |
| Sell | Babylon Holdings Ltd | $31,167,045 | +20.2% | 4,617,340 | -91.6% | 17.58% | -19.1% |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-01
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Babylon Holdings Ltd | 6 | Q1 2023 | 44.6% |
| Teladoc Health, Inc. | 5 | Q4 2022 | 78.3% |
| Recursion Pharmaceuticals, Inc. | 4 | Q3 2023 | 100.0% |
View Kinnevik AB (publ)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. | May 22, 2023 | 10,405,668 | 5.6% |
| Babylon Holdings Ltd | November 14, 2022 | 115,433,522 | 18.6% |
| Teladoc Health, Inc. | April 15, 2021 | 7,491,124 | 4.9% |
| Livongo Health, Inc.Sold out | November 03, 2020 | 0 | 0.0% |
| MILLICOM INTERNATIONAL CELLULAR SASold out | January 21, 2020 | 0 | 0.0% |
View Kinnevik AB (publ)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-15 |
| 13F-HR | 2024-02-02 |
| 13F-HR | 2023-10-06 |
| 13F-HR | 2023-07-25 |
| SC 13G | 2023-05-22 |
| 13F-HR | 2023-04-14 |
| 13F-HR | 2023-02-01 |
| 3 | 2022-12-30 |
| SC 13D | 2022-11-14 |
| 13F-HR | 2022-10-25 |
View Kinnevik AB (publ)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.